Gregory Fraser
Stock Analyst at Truist Securities
(2.60)
# 2,189
Out of 4,944 analysts
37
Total ratings
51.85%
Success rate
14.91%
Average return
Main Sectors:
Stocks Rated by Gregory Fraser
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ANIP ANI Pharmaceuticals | Maintains: Hold | $65 → $77 | $88.74 | -13.23% | 10 | Aug 11, 2025 | |
| JAZZ Jazz Pharmaceuticals | Maintains: Buy | $220 → $230 | $117.12 | +96.38% | 1 | Mar 6, 2025 | |
| BHC Bausch Health Companies | Maintains: Hold | $8 → $7 | $7.17 | -2.37% | 2 | Jul 25, 2024 | |
| XAIR Beyond Air | Maintains: Buy | $200 → $160 | $2.45 | +6,430.61% | 6 | Apr 30, 2024 | |
| BTMD biote | Maintains: Buy | $10 → $9 | $3.09 | +191.73% | 2 | Jan 18, 2024 | |
| AMRX Amneal Pharmaceuticals | Maintains: Buy | $6 → $7 | $9.40 | -25.53% | 4 | Nov 8, 2023 | |
| CORT Corcept Therapeutics | Maintains: Hold | $26 → $29 | $72.80 | -60.16% | 5 | Aug 3, 2023 | |
| NVCR NovoCure | Reiterates: Buy | $95 | $11.62 | +717.56% | 3 | Jun 6, 2023 | |
| EOLS Evolus | Maintains: Buy | $14 → $18 | $6.51 | +176.50% | 2 | May 26, 2023 | |
| ARQT Arcutis Biotherapeutics | Maintains: Buy | $45 → $40 | $15.63 | +155.92% | 2 | May 26, 2023 |
ANI Pharmaceuticals
Aug 11, 2025
Maintains: Hold
Price Target: $65 → $77
Current: $88.74
Upside: -13.23%
Jazz Pharmaceuticals
Mar 6, 2025
Maintains: Buy
Price Target: $220 → $230
Current: $117.12
Upside: +96.38%
Bausch Health Companies
Jul 25, 2024
Maintains: Hold
Price Target: $8 → $7
Current: $7.17
Upside: -2.37%
Beyond Air
Apr 30, 2024
Maintains: Buy
Price Target: $200 → $160
Current: $2.45
Upside: +6,430.61%
biote
Jan 18, 2024
Maintains: Buy
Price Target: $10 → $9
Current: $3.09
Upside: +191.73%
Amneal Pharmaceuticals
Nov 8, 2023
Maintains: Buy
Price Target: $6 → $7
Current: $9.40
Upside: -25.53%
Corcept Therapeutics
Aug 3, 2023
Maintains: Hold
Price Target: $26 → $29
Current: $72.80
Upside: -60.16%
NovoCure
Jun 6, 2023
Reiterates: Buy
Price Target: $95
Current: $11.62
Upside: +717.56%
Evolus
May 26, 2023
Maintains: Buy
Price Target: $14 → $18
Current: $6.51
Upside: +176.50%
Arcutis Biotherapeutics
May 26, 2023
Maintains: Buy
Price Target: $45 → $40
Current: $15.63
Upside: +155.92%